


PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



Keros Therapeutics Inc. Rank 76 of 446



The relative strengths and weaknesses of Keros Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Keros Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 178% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	285,767
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,547
Liabilities, Non-Current	12,811
Other Assets	18,993
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	10,111
Other Revenues	0
Property and Equipment	2,021
Research and Development	87,265
Selling, General and Administrative Expense	27,525

Output Variable	Value in 1000 USD
Assets	306,781
Liabilities	29,358
Expenses	114,790
Revenues	0
Stockholders Equity	277,423
Net Income	-104,679
Comprehensive Net Income	-104,679
Economic Capital Ratio	222%

